Sunil Shah

Sunil Shah serves as the CEO of o2h Ventures and co-founder of o2h Group, where leadership has focused on launching an EIS fund in 2018 to invest in pre-seed and seed capital for British biotech innovations, resulting in over 35 investments. Additional roles include Chairman of the Board at Exonate Limited, Executive Chairman at Alevin Therapeutics Ltd, Board Member at the BioIndustry Association, Oxford Drug Design, Kuano, and Cambridge Angels, as well as Board Observer at Metrion Biosciences and Chairman of the Board at Opal Therapeutics Limited. Sunil Shah is affiliated with Cambridge Judge Business School as an Associate. Academic qualifications include an MBA from the University of Cambridge and a BSc in Biochemistry and Management Sciences from Keele University.